Trial
NCT04856176
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Tufts Medical Center
Collaborators
Partner Therapeutics, Inc.
Condition
Advanced Lung Non-Small Cell Carcinoma
Intervention
Granulocyte-Macrophage Colony-Stimulating Factor
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-01